Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care

Lung Cancer

Volumn 75, Issue 3, 2012, Pages 269-274

  Pallis, Athanasios G ^a   Georgoulias, Vassilis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Doublet chemotherapy; First line; Meta analysis; NSCLC; Platinum based chemotherapy; Treatment duration

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; PEMETREXED; TAXANE DERIVATIVE; TIRAPAZAMINE; VINCA ALKALOID; VINDESINE;

ANEMIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; MORTALITY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; HUMANS; LUNG NEOPLASMS; META-ANALYSIS AS TOPIC; PLATINUM; STANDARD OF CARE;

EID: 84856585788     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.09.010     Document Type: Review

References (49)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J Clin 2009.
2. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18(3):581-592.
3. Yang P., Allen M.S., Aubry M.C., Wampfler J.A., Marks R.S., Edell E.S., et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005, 128(1):452-462.
4. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24(28):4539-4544.
5. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22(2):330-353.
6. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-98.
7. Fossella F., Pereira J.R., von P.J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21(16):3016-3024.
8. Kubota K., Watanabe K., Kunitoh H., Noda K., Ichinose Y., Katakami N., et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study group. J Clin Oncol 2004, 22(2):254-261.
9. Scagliotti G.V., De M.F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20(21):4285-4291.
10. Douillard J.Y., Gervais R., Dabouis G., Le G.A., D'Arlhac M., Spaeth D., et al. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study. Ann Oncol 2005, 16(1):81-89.
11. Georgoulias V., Papadakis E., Alexopoulos A., Tsiafaki X., Rapti A., Veslemes M., et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001, 357(9267):1478-1484.
12. Georgoulias V., Ardavanis A., Tsiafaki X., Agelidou A., Mixalopoulou P., Anagnostopoulou O., et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2005, 23(13):2937-2945.
13. Kosmidis P., Mylonakis N., Nicolaides C., Kalophonos C., Samantas E., Boukovinas J., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002, 20(17):3578-3585.
14. Gridelli C., Gallo C., Shepherd F.A., Illiano A., Piantedosi F., Robbiati S.F., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials group. J Clin Oncol 2003, 21(16):3025-3034.
15. Smit E.F., van Meerbeeck J.P., Lianes P., Debruyne C., Legrand C., Schramel F., et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer group-EORTC 08975. J Clin Oncol 2003, 21(21):3909-3917.
16. Pujol J.L., Breton J.L., Gervais R., Rebattu P., Depierre A., Morere J.F., et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005, 16(4):602-610.
17. Socinski M.A., Crowell R., Hensing T.E., Langer C.J., Lilenbaum R., Sandler A.B., et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(3 Suppl.):277S-289S.
18. Scagliotti G.V., Parikh P., von P.J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
19. Brockwell S.E., Gordon I.R. A comparison of statistical methods for meta-analysis. Stat Med 2001, 20(6):825-840.
20. Normand S.L. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999, 18(3):321-359.
21. Buyse M., Piedbois P., Piedbois Y., Carlson R.W. Meta-analysis: methods, strengths, and weaknesses. Oncology (Williston Park) 2000, 14(3):437-443.
22. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer collaborative group. BMJ 1995, 311(7010):899-909.
23. Delbaldo C., Michiels S., Syz N., Soria J.C., Le C.T., Pignon J.P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004, 292(4):470-484.
24. Lilenbaum R.C., Langenberg P., Dickersin K. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival. Cancer 1998, 82(1):116-126.
25. Azim H.A., Elattar I., Loberiza F.R., Azim H., Mok T., Ganti A.K. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview. Lung Cancer 2009, 64(2):194-198.
26. Muggia F.M. Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin Oncol 1989, 16(2 Suppl. 5):7-13.
27. Zatloukal P., Petruzelka L., Zemanova M., Kolek V., Skrickova J., Pesek M., et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003, 41(3):321-331.
28. Jelic S., Mitrovic L., Radosavljevic D., Elezar E., Babovic N., Kovcin V., et al. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study. Lung Cancer 2001, 34(1):1-13.
29. Kelly K., Crowley J., Bunn P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology group trial. J Clin Oncol 2001, 19(13):3210-3218.
30. Rosell R., Gatzemeier U., Betticher D.C., Keppler U., Macha H.N., Pirker R., et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002, 13(10):1539-1549.
31. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004, 22(19):3852-3859.
32. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99(11):847-857.
33. Jiang J., Liang X., Zhou X., Huang R., Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2007, 57(3):348-358.
34. Pujol J.L., Carestia L., Daures J.P. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000, 83(1):8-15.
35. Pujol J.L., Barlesi F., Daures J.P. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 2006, 51(3):335-345.
36. D'Addario G., Pintilie M., Leighl N.B., Feld R., Cerny T., Shepherd F.A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005, 23(13):2926-2936.
37. Rajeswaran A., Trojan A., Burnand B., Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008, 59(1):1-11.
38. Baggstrom M.Q., Stinchcombe T.E., Fried D.B., Poole C., Hensing T.A., Socinski M.A. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2007, 2(9):845-853.
39. Le C.T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005, 47(1):69-80.
40. Gao G., Jiang J., Liang X., Zhou X., Huang R., Chu Z., et al. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer. Lung Cancer 2009, 65(3):339-344.
41. Douillard J.Y., Laporte S., Fossella F., Georgoulias V., Pujol J.L., Kubota K., et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007, 2(10):939-946.
42. Grossi F., Aita M., Defferrari C., Rosetti F., Brianti A., Fasola G., et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 2009, 14(5):497-510.
43. Sekine I., Tamura T., Kunitoh H., Kubota K., Shinkai T., Kamiya Y., et al. Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer. Ann Oncol 1999, 10(6):731-733.
44. Carney D.N. Lung cancer - time to move on from chemotherapy. N Engl J Med 2002, 346(2):126-128.
45. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
46. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
47. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
48. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
49. Zhou C., Wu Y.L., Chen G., Feng J., Liu X., Wang C., et al. Efficacy results from the randomised Phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus Carboplatin (Cbdca) plus Gemcitabine (Gem), in Chinese advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (Pts) With Egfr activating mutations. Ann Oncol 2010, 21(Suppl. 8). [abstr LBA 13].